OPKO Health, Inc. (0KCS.L)
USD 1.41
(3.82%)
USD 1.41
(3.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -65.51 Million USD | 70.41% |
| 2022 | -270.81 Million USD | -6957.69% |
| 2021 | 83.57 Million USD | -97.55% |
| 2020 | 139.08 Million USD | 295.4% |
| 2019 | -189.64 Million USD | 41.8% |
| 2018 | -68.03 Million USD | 44.03% |
| 2017 | -163.23 Million USD | -764.16% |
| 2016 | 30.46 Million USD | 125.48% |
| 2015 | -87.33 Million USD | 32.44% |
| 2014 | -143.83 Million USD | -359.01% |
| 2013 | -75.2 Million USD | -27.76% |
| 2012 | -25.64 Million USD | -30.37% |
| 2011 | -19.39 Million USD | -135.88% |
| 2010 | -8.55 Million USD | 56.96% |
| 2009 | -22.81 Million USD | 44.66% |
| 2008 | -35.47 Million USD | -115.34% |
| 2007 | -23.91 Million USD | 19911.73% |
| 2006 | -1.11 Million USD | 55.3% |
| 2005 | -181 Thousand USD | -22.14% |
| 2004 | -1.91 Million USD | -41.69% |
| 2003 | -3.67 Million USD | 77.93% |
| 2002 | -8.54 Million USD | 37.73% |
| 2001 | -10.23 Million USD | -26.37% |
| 2000 | -8.31 Million USD | -110.43% |
| 1999 | -3.95 Million USD | -23.47% |
| 1998 | -2.9 Million USD | 3.03% |
| 1997 | -3.2 Million USD | -6.45% |
| 1996 | -2.9 Million USD | -106.67% |
| 1995 | -1.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -45.65 Million USD | -15.35% |
| 2024 Q2 | -37.51 Million USD | 143.78% |
| 2023 Q1 | -8.9 Million USD | 78.45% |
| 2023 Q2 | 13.19 Million USD | 248.29% |
| 2023 Q3 | -45.1 Million USD | -441.72% |
| 2023 FY | - USD | 70.41% |
| 2023 Q4 | -43.11 Million USD | 4.39% |
| 2022 Q2 | -70.77 Million USD | -53.35% |
| 2022 Q1 | -46.14 Million USD | 9.16% |
| 2022 FY | - USD | -6957.69% |
| 2022 Q3 | -98.17 Million USD | -38.72% |
| 2022 Q4 | -41.3 Million USD | 57.93% |
| 2021 FY | - USD | -97.55% |
| 2021 Q1 | 56.54 Million USD | 10.23% |
| 2021 Q4 | -50.8 Million USD | -336.96% |
| 2021 Q3 | 21.43 Million USD | 50.3% |
| 2021 Q2 | 14.26 Million USD | -74.78% |
| 2020 Q4 | 51.3 Million USD | 5.23% |
| 2020 Q1 | -31.76 Million USD | -155.82% |
| 2020 Q3 | 48.74 Million USD | -29.13% |
| 2020 FY | - USD | 295.4% |
| 2020 Q2 | 68.78 Million USD | 316.57% |
| 2019 Q4 | 56.9 Million USD | 281.0% |
| 2019 Q1 | -47.7 Million USD | -23.26% |
| 2019 Q2 | -32.67 Million USD | 31.5% |
| 2019 Q3 | -31.43 Million USD | 3.79% |
| 2019 FY | - USD | 41.8% |
| 2018 Q3 | -9.13 Million USD | -170.74% |
| 2018 Q4 | -38.7 Million USD | -323.88% |
| 2018 Q1 | -21.9 Million USD | 81.84% |
| 2018 FY | - USD | 44.03% |
| 2018 Q2 | 12.9 Million USD | 158.93% |
| 2017 Q4 | -120.6 Million USD | -178.77% |
| 2017 Q3 | -43.26 Million USD | -1505.95% |
| 2017 Q1 | -10.31 Million USD | 66.18% |
| 2017 Q2 | 3.07 Million USD | 129.83% |
| 2017 FY | - USD | -764.16% |
| 2016 FY | - USD | 125.48% |
| 2016 Q4 | -30.5 Million USD | -5183.33% |
| 2016 Q3 | 600 Thousand USD | -99.14% |
| 2016 Q2 | 69.71 Million USD | 2441.62% |
| 2016 Q1 | -2.97 Million USD | 62.32% |
| 2015 Q4 | -7.9 Million USD | -133.91% |
| 2015 Q1 | -49.71 Million USD | -52.97% |
| 2015 Q2 | -20.82 Million USD | 58.11% |
| 2015 Q3 | 23.29 Million USD | 211.88% |
| 2015 FY | - USD | 32.44% |
| 2014 Q4 | -32.5 Million USD | -19.08% |
| 2014 Q2 | -15.93 Million USD | 28.39% |
| 2014 FY | - USD | -359.01% |
| 2014 Q1 | -22.24 Million USD | -295.34% |
| 2014 Q3 | -27.29 Million USD | -71.33% |
| 2013 Q2 | -3.83 Million USD | -1084.1% |
| 2013 FY | - USD | -27.76% |
| 2013 Q4 | -5.62 Million USD | 75.2% |
| 2013 Q3 | -22.68 Million USD | -491.17% |
| 2013 Q1 | 390 Thousand USD | 105.17% |
| 2012 Q3 | -6.09 Million USD | -3.81% |
| 2012 Q2 | -5.87 Million USD | 9.5% |
| 2012 Q4 | -7.54 Million USD | -23.64% |
| 2012 Q1 | -6.49 Million USD | 18.56% |
| 2012 FY | - USD | -30.37% |
| 2011 Q3 | -4.18 Million USD | -6.35% |
| 2011 FY | - USD | -135.88% |
| 2011 Q4 | -7.97 Million USD | -90.35% |
| 2011 Q2 | -3.93 Million USD | 4.58% |
| 2011 Q1 | -4.12 Million USD | -1411.72% |
| 2010 FY | - USD | 56.96% |
| 2010 Q2 | -4.14 Million USD | -50.42% |
| 2010 Q4 | -273 Thousand USD | 94.89% |
| 2010 Q1 | -2.75 Million USD | -59.99% |
| 2010 Q3 | -5.34 Million USD | -28.98% |
| 2009 Q2 | -4.28 Million USD | 44.12% |
| 2009 Q1 | -7.66 Million USD | 30.14% |
| 2009 FY | - USD | 44.66% |
| 2009 Q4 | -1.72 Million USD | 65.07% |
| 2009 Q3 | -4.93 Million USD | -15.08% |
| 2008 Q4 | -10.97 Million USD | -53.02% |
| 2008 FY | - USD | -115.34% |
| 2008 Q1 | -9.91 Million USD | -22.28% |
| 2008 Q2 | -7.17 Million USD | 27.66% |
| 2008 Q3 | -7.17 Million USD | -0.01% |
| 2007 Q1 | 487.52 Million USD | 102306.92% |
| 2007 Q4 | -8.1 Million USD | -459.9% |
| 2007 Q3 | 2.25 Million USD | 121.45% |
| 2007 Q2 | -10.5 Million USD | -102.15% |
| 2007 FY | - USD | 19911.73% |
| 2006 Q2 | -170 Thousand USD | 48.95% |
| 2006 Q3 | -392 Thousand USD | -130.59% |
| 2006 Q4 | -477 Thousand USD | -21.68% |
| 2006 FY | - USD | 55.3% |
| 2006 Q1 | -333 Thousand USD | 2.06% |
| 2005 Q2 | -533 Thousand USD | -43.67% |
| 2005 FY | - USD | -22.14% |
| 2005 Q4 | -340 Thousand USD | 72.99% |
| 2005 Q3 | -1.25 Million USD | -136.21% |
| 2005 Q1 | -371 Thousand USD | -14.86% |
| 2004 Q4 | -323 Thousand USD | 24.53% |
| 2004 FY | - USD | -41.69% |
| 2004 Q2 | -588 Thousand USD | 26.22% |
| 2004 Q3 | -428 Thousand USD | 27.21% |
| 2004 Q1 | -797 Thousand USD | -131.1% |
| 2003 Q2 | -1.83 Million USD | -66.21% |
| 2003 Q1 | -1.02 Million USD | -6253.33% |
| 2003 Q3 | -1.55 Million USD | 7.2% |
| 2003 FY | - USD | 77.93% |
| 2003 Q4 | 737 Thousand USD | 274.35% |
| 2002 Q1 | -1.86 Million USD | 20.79% |
| 2002 Q2 | -1.95 Million USD | -4.49% |
| 2002 FY | - USD | 37.73% |
| 2002 Q3 | -2.7 Million USD | -38.21% |
| 2002 Q4 | -2.02 Million USD | 99.44% |
| 2001 Q3 | -2.84 Million USD | 12.81% |
| 2001 Q4 | -2.36 Million USD | 16.98% |
| 2001 FY | - USD | -26.37% |
| 2001 Q1 | -1.71 Million USD | 4.51% |
| 2001 Q2 | -3.26 Million USD | -90.26% |
| 2000 FY | - USD | -110.43% |
| 2000 Q1 | -2.45 Million USD | -133.87% |
| 2000 Q4 | -1.79 Million USD | 24.41% |
| 2000 Q2 | -1.68 Million USD | 31.49% |
| 2000 Q3 | -2.37 Million USD | -41.09% |
| 1999 Q3 | -900 Thousand USD | -28.57% |
| 1999 FY | - USD | -23.47% |
| 1999 Q4 | -1.05 Million USD | -16.78% |
| 1999 Q2 | -750 Thousand USD | 46.15% |
| 1999 Q1 | -1.3 Million USD | -30.0% |
| 1998 Q4 | -1 Million USD | 16.67% |
| 1998 FY | - USD | 3.03% |
| 1998 Q1 | -700 Thousand USD | 12.5% |
| 1998 Q2 | -400 Thousand USD | 42.86% |
| 1998 Q3 | -1.2 Million USD | -200.0% |
| 1997 FY | - USD | -6.45% |
| 1997 Q1 | -600 Thousand USD | 25.0% |
| 1997 Q2 | -600 Thousand USD | 0.0% |
| 1997 Q3 | -900 Thousand USD | -50.0% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1996 FY | - USD | -106.67% |
| 1996 Q1 | -700 Thousand USD | 0.0% |
| 1996 Q2 | -700 Thousand USD | 0.0% |
| 1996 Q3 | -700 Thousand USD | 0.0% |
| 1996 Q4 | -800 Thousand USD | -14.29% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 59.835% |
| Dynavax Technologies Corporation | 9.66 Million USD | 777.798% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 44.313% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.419% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 166.675% |
| Perrigo Company plc | 646.2 Million USD | 110.139% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 75.37% |
| Illumina, Inc. | -608 Million USD | 89.224% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.607% |
| Nektar Therapeutics | -243.1 Million USD | 73.051% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 85.409% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.012% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 36.878% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -75.726% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 121.115% |
| Waters Corporation | 1.02 Billion USD | 106.409% |
| Biogen Inc. | 2.37 Billion USD | 102.756% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 25.062% |
| Adicet Bio, Inc. | -136.53 Million USD | 52.015% |
| Evolus, Inc. | -41.81 Million USD | -56.699% |
| bluebird bio, Inc. | -167.16 Million USD | 60.807% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 25.537% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 56.354% |
| FibroGen, Inc. | -261.4 Million USD | 74.937% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 103.907% |
| Homology Medicines, Inc. | -47.75 Million USD | -37.189% |
| Geron Corporation | -174.78 Million USD | 62.516% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 71.28% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -47.437% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 28.848% |
| Myriad Genetics, Inc. | -67.8 Million USD | 3.369% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.408% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 35.021% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 87.06% |
| Zoetis Inc. | 3.68 Billion USD | 101.778% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -29.55% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 105.628% |
| Exelixis, Inc. | 196.6 Million USD | 133.324% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.423% |
| uniQure N.V. | -253.1 Million USD | 74.115% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -81.575% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -17.505% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 70.881% |
| Verastem, Inc. | -83.16 Million USD | 21.223% |
| Imunon, Inc. | -20.78 Million USD | -215.249% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 71.516% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 85.083% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 115.745% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 160.482% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 114.496% |
| TG Therapeutics, Inc. | 26.1 Million USD | 351.019% |
| Blueprint Medicines Corporation | -474.61 Million USD | 86.196% |
| Insmed Incorporated | -654.73 Million USD | 89.994% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 81.035% |
| Incyte Corporation | 919.42 Million USD | 107.126% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 87.034% |